search
Back to results

Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission

Primary Purpose

HIV Infections, AIDS, Sexually Transmitted Diseases

Status
Completed
Phase
Phase 3
Locations
South Africa
Study Type
Interventional
Intervention
Carraguard (PC-515)
Sponsored by
Population Council
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for HIV Infections focused on measuring Microbicide, HIV, AIDS, STIs, STDs, Efficacy, HSV, Women, South Africa, seroconversion, condom, safe-sex, vaginal intercourse, prevention, HIV Seronegativity

Eligibility Criteria

16 Years - 40 Years (Child, Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: HIV negative and agree to be tested for HIV and told their results at all visits during the study Aged 16 - 40 years of age Have had at least one vaginal intercourse within the last three months Willing and able to give written informed consent (or if desired, consent provided by parent or guardian with written assent from the minor participant) Provide locator information to study staff throughout the trial Comply with all aspects of the study protocol, including random assignment to the Carraguard® plus condom or placebo plus condom arm, clinical valuations, specimen collection and testing, visit schedule and study drug regimen Citizen or permanent resident of South Africa Resident for the past year and intends to reside in the catchment area of the site for the next two years During the study, will not use any vaginal products except tampons or those prescribed or approved by the study clinician. Exclusion Criteria: Currently pregnant, or indicate a desire to become pregnant in the next two years at the time of screening Within four weeks of last pregnancy outcome at the time of enrolment Pap smear at screening is graded as carcinoma. Injected illicit drugs in the 12 months prior to screening Participating in any other clinical trial/HIV prevention study

Sites / Locations

  • Isipingo Clinic
  • Empilisweni Clinic
  • Setshaba Research Clinic, University of Limpopo - Medunsa Campus

Outcomes

Primary Outcome Measures

Time to HIV seroconversion during trial participation (evaluated quarterly)

Secondary Outcome Measures

Determine long-term safety based on the incidence of sexually transmitted infections (STI), Chlamydia, gonorrhoeae, trichomoniasis, and syphilis tests and the number of adverse events and serious adverse events
Chlamydia, gonorrhoeae, trichomoniasis and syphilis tests are conducted at months 3, 6, 12, 18 and 24 and as clinically indicated

Full Information

First Posted
September 13, 2005
Last Updated
August 11, 2017
Sponsor
Population Council
Collaborators
United States Agency for International Development (USAID), Bill and Melinda Gates Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00213083
Brief Title
Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission
Official Title
Phase 3 Study of the Efficacy and Safety of the Microbicide Carraguard® in Preventing HIV Seroconversion in Women
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
April 2004 (undefined)
Primary Completion Date
April 2007 (Actual)
Study Completion Date
April 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Population Council
Collaborators
United States Agency for International Development (USAID), Bill and Melinda Gates Foundation

4. Oversight

5. Study Description

Brief Summary
The purposes of this study are to determine whether Carraguard® Gel can prevent the transmission of HIV when used during vaginal intercourse, and to confirm that the gel is safe for vaginal use.
Detailed Description
This study is designed to show if Carraguard® can protect women against HIV if it is used before sex, and is safe for long-term use.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections, AIDS, Sexually Transmitted Diseases, HIV Seroconversion
Keywords
Microbicide, HIV, AIDS, STIs, STDs, Efficacy, HSV, Women, South Africa, seroconversion, condom, safe-sex, vaginal intercourse, prevention, HIV Seronegativity

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
6203 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Carraguard (PC-515)
Primary Outcome Measure Information:
Title
Time to HIV seroconversion during trial participation (evaluated quarterly)
Secondary Outcome Measure Information:
Title
Determine long-term safety based on the incidence of sexually transmitted infections (STI), Chlamydia, gonorrhoeae, trichomoniasis, and syphilis tests and the number of adverse events and serious adverse events
Title
Chlamydia, gonorrhoeae, trichomoniasis and syphilis tests are conducted at months 3, 6, 12, 18 and 24 and as clinically indicated

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: HIV negative and agree to be tested for HIV and told their results at all visits during the study Aged 16 - 40 years of age Have had at least one vaginal intercourse within the last three months Willing and able to give written informed consent (or if desired, consent provided by parent or guardian with written assent from the minor participant) Provide locator information to study staff throughout the trial Comply with all aspects of the study protocol, including random assignment to the Carraguard® plus condom or placebo plus condom arm, clinical valuations, specimen collection and testing, visit schedule and study drug regimen Citizen or permanent resident of South Africa Resident for the past year and intends to reside in the catchment area of the site for the next two years During the study, will not use any vaginal products except tampons or those prescribed or approved by the study clinician. Exclusion Criteria: Currently pregnant, or indicate a desire to become pregnant in the next two years at the time of screening Within four weeks of last pregnancy outcome at the time of enrolment Pap smear at screening is graded as carcinoma. Injected illicit drugs in the 12 months prior to screening Participating in any other clinical trial/HIV prevention study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pekka Lahteenmaki, MD, PhD
Organizational Affiliation
Population Council, Center for Biomedical Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Isipingo Clinic
City
Overport
State/Province
Durban
ZIP/Postal Code
4067
Country
South Africa
Facility Name
Empilisweni Clinic
City
Cape Town
ZIP/Postal Code
7925
Country
South Africa
Facility Name
Setshaba Research Clinic, University of Limpopo - Medunsa Campus
City
Medunsa
ZIP/Postal Code
0204
Country
South Africa

12. IPD Sharing Statement

Citations:
PubMed Identifier
15776387
Citation
Skoler S, Govender S, Altini L, Ahmed K, Waldron D, Myer L, Lahteenmaki P. Risks in the use of an unblinded-control group. J Infect Dis. 2005 Apr 15;191(8):1378-9; author reply 1379-80. doi: 10.1086/427833. No abstract available.
Results Reference
background
PubMed Identifier
17586138
Citation
Wallace AR, Teitelbaum A, Wan L, Mulima MG, Guichard L, Skoler S, Vilakazi H, Mapula FS, Rossier J, Govender SN, Lahteenmaki P, Maguire RA, Phillips DM. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007 Jul;76(1):53-6. doi: 10.1016/j.contraception.2006.10.012. Epub 2007 May 11. Erratum In: Contraception. 2007 Oct;76(4):335. Skiler, Stephanie [corrected to Skoler, Stephanie].
Results Reference
background
PubMed Identifier
16608384
Citation
Singh JA, Karim SS, Karim QA, Mlisana K, Williamson C, Gray C, Govender M, Gray A. Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa. PLoS Med. 2006 Jul;3(7):e180. doi: 10.1371/journal.pmed.0030180. Epub 2006 Apr 18.
Results Reference
background
PubMed Identifier
19059048
Citation
Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Dec 6;372(9654):1977-87. doi: 10.1016/S0140-6736(08)61842-5.
Results Reference
derived
Links:
URL
http://www.popcouncil.org
Description
Official website of the Population Council

Learn more about this trial

Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission

We'll reach out to this number within 24 hrs